Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer

Fig. 1

IGF2BP2 is associated with tumor growth and patients’ outcome in CRC. A RNA expression using RPKM values of IGF2BP1-3 in normal colon tissue (colon, n = 22), primary tumor tissue (primary tumor, n = 88), non-neoplastic hepatic tissue (liver, n = 12), and tissue from liver metastases (liver metastases, n = 23) was determined by RNA-Seq [31]. Statistical significance was determined by Mann-Whitney U Test as data were not normally distributed. B Representative images of immunohistochemical staining against IGF2BP2 in a) normal colon tissue, b) primary tumor tissue, c) and d) liver metastasis with normal hepatic tissue. Scale bar = 100 µm, original magnification was 200x. C Immunohistochemistry for IGF2BP2 was scored for staining intensity. Samples with low (scores 1–2.49) or high intensity (score 2.5–3) were grouped regarding tumor stages I/II and III/IV. Statistical significance was determined by Fisher´s exact test. D Tumor growth in cm3 of PDXs was correlated with IGF2BP2 expression of primary tumor tissue. Pearson correlation is shown for day 46 after tumor transplantation

Back to article page

Molecular Cancer

ISSN: 1476-4598